BCI Pharma moves forward with 2 series of best-in-class kinase inhibitors (FLT3 and CSF1R).
The FLT3 is the most advanced project and a preclinical candidate (BCI-1446) very active in animal models of neuropathic pain (Bennett, STZ and Paclitaxel) enter into regulatory toxicological studies.
BCI-1446 will be also explored in psoriasis animal model.
Our platform delivered also the best-in-class CSF1R inhibitors which will be explored in central (MS, ALS) and peripheral (IBD, RA) inflammation animal models.
Our preclinical candidate BCI-1445 shows high efficacy in animal models of chronic pain.